Vimian Group, a veterinary company, agreed to acquire Bova Holdings, an animal health specialty pharmaceuticals company for $100m. “The acquisition of Bova marks an important milestone in our strategic ambition to add new therapeutic areas to Vimian’s Specialty Pharma segment. Bova holds a unique position in the UK as the leading innovator in specialty pharmaceuticals for companion animal health and enjoys a strong financial position with high growth and high margins having grown with more than 70 percent over the past year,” Magnus Kjellberg, Vimian Specialty Pharma segment Nextmune CEO.